# Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis

> **NCT03520439** · PHASE2,PHASE3 · COMPLETED · sponsor: **xinmei zhang** · enrollment: 134 (actual)

## Conditions studied

- Adenomyosis

## Interventions

- **DRUG:** Mifepristone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03520439
- **Lead sponsor:** xinmei zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-19
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-10-01
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2019-10-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03520439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03520439, "Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03520439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*